W e read with interest the report by Kim et al 1 regarding a predictive model for progression of indeterminate pulmonary nodules (IPNs) in patients with colorectal cancer (CRC). This topic is clinically relevant, given that the presence of IPNs can affect the treatment strategy, especially in patients with liver metastases who may require sequential or combined liver and lung resections.
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2,3 The predictive model was developed on the basis of a thorough analysis of clinicopathological data. However, we believe that consideration of RAS mutation status would have improved the accuracy of the model, given the evidence reported in modern series.
During the past decade, somatic mutation of the RAS oncogene family has become a focus of CRC research and studies have demonstrated that RAS mutation status correlates with the tumor biology of CRC. 4 Especially, growing evidence reveals a propensity for RAS-mutated tumors to metastasize to the lung. [5] [6] [7] Tie et al 6 demonstrated that KRAS mutation prevalence was significantly higher in lung (62%) and brain metastases of CRC (57%) than in liver metastases (32%), indicating the metastatic site-specific association of KRAS mutation status. In addition, we recently reported that patients with mutant RAS had a lower 3-year lung recurrence-free survival rate (35% vs 59%; P < .01) but not a lower liver recurrence-free survival rate (44% vs 50%; P ¼ 0.18) than patients with wild-type RAS after hepatectomy for colorectal liver metastases.
7
As we previously proposed, these findings suggest that RAS mutation may also predict a high propensity for lung metastases in patients with IPNs.
7 From a practical perspective, the reported high concordance of mutation status between primary and metastatic tumors may allow for early identification of patients at risk for progression of IPNs-that is, patients with RAS mutation in their primary tumors. [6] [7] [8] [9] In the study by Kim et al, multivariate analysis revealed that primary tumor characteristics (rectal primary tumor, positive node status, and perineural invasion) and IPN characteristics (metachronous and bilateral presentation) were strong predictors of progression of IPNs. We believe that additional investigation of the genetic profile of the primary tumor would have resulted in a more powerful predictive model for progression of IPNs. We thank Dr Kim and colleagues both for investigating an important issue and for providing a thorough predictive model for progression of IPNs. 
Reply:
W e appreciate the comments by Yoshihiro et al that RAS mutations in the primary tumor could predict a high propensity for lung metastasis. As mentioned, Vauthey et al 1 have suggested that the RAS status be incorporated into the predictive model for lung metastasis and ultimately used as a guide in the surveillance program. However, we think that the prediction of lung metastasis and utilization of a surveillance guide considering the KRAS mutation alone may be insufficient in different clinical settings. In our study, the anatomic location, pathologic disease status, and radiologic findings were independent predictors of progression of indeterminate pulmonary nodules (IPNs). Unfortunately, because we do not have data on the KRAS status of tumors included in our study, we cannot discern with certainty whether the KRAS mutation status would remain significant after adjusting these factors. In this regard, Tie et al 3 reported that lung metastases developed more frequently in tumors with KRAS mutations than in KRAS wild-type cancers, with an estimated hazard ratio of 2.1. In addition, the presence of a KRAS mutation was verified as a significant factor on multivariate analysis in their study, especially after adjusting for the tumor site and pathologic tumor stage. Taken together, this biological biomarker of colorectal cancer may potentially improve the discriminative power of our model. For example, the observation that some patients with colon cancer experience lung metastases without liver metastases opposite to their respective anatomic vascular drainage system could be explained by a peculiar biological mechanism of carcinogenesis or a special susceptibility of the lung parenchyma to tumors with KRAS mutations. 4 In our study, in 8 (14.8%) of the 54 patients whose tumor was located in the colon rather than in the rectum, IPNs progressed to definite pulmonary metastases.
2 Therefore, using the KRAS mutation status in this subgroup could provide a more detailed stratification in our prediction model.
In the era of modern systemic chemotherapy and biological agents, we expect to encounter clinical dilemmas associated with IPNs more frequently. Because
